-
1.发明申请Recombinant Human Albumin-Granulocyte Macrophage Colony Stimulating Factor Fusion Protein With Long-Lasting Biological Effects 审中-公开重组人白蛋白 - 粒细胞巨噬细胞集落刺激因子融合蛋白与持久的生物效应公开(公告)号：US20120128624A1
公开(公告)日：2012-05-24
申请号：US13327621
申请日：2011-12-15
IPC: A61K38/38 , C12N15/62 , C12N15/63 , C12N1/19 , C12N15/85 , C12N15/81 , C12N5/10 , C12N1/21 , C07K19/00 , C12N15/82
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。
-
2.发明授权Recombinant human albumin-interleukin-11 fusion protein with long-lasting biological effects 有权重组人白蛋白 - 白细胞介素-11融合蛋白具有持久的生物学效应公开(公告)号：US08084021B2
公开(公告)日：2011-12-27
申请号：US12203116
申请日：2008-09-02
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。
-
3.发明授权Recombinant human albumin fusion proteins with long-lasting biological effects 有权重组人白蛋白融合蛋白具有持久的生物学效应公开(公告)号：US07244833B2
公开(公告)日：2007-07-17
申请号：US10609346
申请日：2003-06-26
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。
-
4.发明授权Method of use and preparation of HSA fusion protein composition for skincare 有权HSA融合蛋白组合物用于护肤品的使用和制备方法公开(公告)号：US09114094B2
公开(公告)日：2015-08-25
申请号：US14064701
申请日：2013-10-28
IPC: A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , C12N15/00 , C12N15/09 , C12N15/11 , C12N15/12 , C12N15/62 , C12N15/63 , C12N15/81 , A61K8/64 , A61K9/00 , A61K9/06 , A61K9/107 , A61K38/38 , A61Q19/02 , A61Q19/08 , C07K14/475 , A61K38/19 , A61K38/20 , A61K38/21 , A61K38/30 , A61K36/064 , A61K8/99 , A61Q5/12 , A61Q11/00 , A61Q19/00
CPC classification number: A61K8/64 , A61K8/99 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K36/064 , A61K38/1808 , A61K38/1816 , A61K38/1858 , A61K38/193 , A61K38/20 , A61K38/217 , A61K38/30 , A61K38/38 , A61Q5/12 , A61Q11/00 , A61Q19/00 , A61Q19/02 , A61Q19/08 , C07K14/475 , C07K2319/00 , A61K2300/00
Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
Abstract translation: 本发明提供了一种重组融合蛋白，其能刺激皮肤和表皮细胞的复原和再激活，以改善皮肤外观，使皱纹和雀斑平滑，以及美白皮肤。 特别地，本发明提供各种类型的用于改善皮肤的产品，其含有人血清白蛋白（HSA）与细胞因子肽（EGF，FGF，KGF，HGH，HGF，PDGF，GCSF，干扰素，IL-11或 IGF）通过基因工程技术。 融合蛋白可以独立使用或与酵母发酵产物组合使用，或与各种乳化剂，增稠剂，保湿剂，防腐剂，酵母和发酵剂组合使用。
-
5.发明申请Method of Use and Preparation of HSA Fusion Protein Composition for Skincare 有权HSA融合蛋白组合物用于护肤品的使用和制备方法公开(公告)号：US20140099270A1
公开(公告)日：2014-04-10
申请号：US14064701
申请日：2013-10-28
CPC classification number: A61K8/64 , A61K8/99 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K36/064 , A61K38/1808 , A61K38/1816 , A61K38/1858 , A61K38/193 , A61K38/20 , A61K38/217 , A61K38/30 , A61K38/38 , A61Q5/12 , A61Q11/00 , A61Q19/00 , A61Q19/02 , A61Q19/08 , C07K14/475 , C07K2319/00 , A61K2300/00
Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
Abstract translation: 本发明提供了一种重组融合蛋白，其能刺激皮肤和表皮细胞的复原和再激活，以改善皮肤外观，使皱纹和雀斑平滑，以及美白皮肤。 特别地，本发明提供各种类型的用于改善皮肤的产品，其含有人血清白蛋白（HSA）与细胞因子肽（EGF，FGF，KGF，HGH，HGF，PDGF，GCSF，干扰素，IL-11或 IGF）通过基因工程技术。 融合蛋白可以独立使用或与酵母发酵产物组合使用，或与各种乳化剂，增稠剂，保湿剂，防腐剂，酵母和发酵剂组合使用。
-
Patent Agency Ranking
6.发明申请Recombinant Human Albumin-Interleukin-11 Fusion Protein With Long-Lasting Biological Effects 有权重组人白细胞介素-11融合蛋白具有持久的生物学效应公开(公告)号：US20100068173A1
公开(公告)日：2010-03-18
申请号：US12203116
申请日：2008-09-02
IPC: A61K38/20 , C07K14/54 , C07H21/00 , C12N15/63 , C12N5/00 , C12N5/07 , C12N5/04 , C12N1/19 , C12N1/21 , A61P43/00
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。
-
7.发明申请Recombinant human albumin fusion proteins with long-lasting biological effects 有权重组人白蛋白融合蛋白具有持久的生物学效应公开(公告)号：US20080009446A1
公开(公告)日：2008-01-10
申请号：US11825686
申请日：2007-07-08
IPC: A61K38/17 , C07H21/04 , C07K14/00 , C07K14/765 , C12N1/16 , C12N1/20 , C12N15/63 , C12N5/04 , C12N5/06
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。
-
8.发明授权Skincare composition comprising HSA fusion protein, preparation method and uses thereof 有权包含HSA融合蛋白的护肤组合物，其制备方法和用途公开(公告)号：US08603973B2
公开(公告)日：2013-12-10
申请号：US12529981
申请日：2008-09-24
CPC classification number: A61K8/64 , A61K8/99 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K36/064 , A61K38/1808 , A61K38/1816 , A61K38/1858 , A61K38/193 , A61K38/20 , A61K38/217 , A61K38/30 , A61K38/38 , A61Q5/12 , A61Q11/00 , A61Q19/00 , A61Q19/02 , A61Q19/08 , C07K14/475 , C07K2319/00 , A61K2300/00
Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
Abstract translation: 本发明提供了一种重组融合蛋白，其能刺激皮肤和表皮细胞的复原和再激活，以改善皮肤外观，使皱纹和雀斑平滑，以及美白皮肤。 特别地，本发明提供各种类型的用于改善皮肤的产品，其含有人血清白蛋白（HSA）与细胞因子肽（EGF，FGF，KGF，HGH，HGF，PDGF，GCSF，干扰素，IL-11或 IGF）通过基因工程技术。 融合蛋白可以独立使用或与酵母发酵产物组合使用，或与各种乳化剂，增稠剂，保湿剂，防腐剂，酵母和发酵剂组合使用。
-
9.发明申请Skincare Composition Comprising HSA Fusion Protein, Preparation Method And Uses Thereof 有权包含HSA融合蛋白的护肤组合物，其制备方法和用途公开(公告)号：US20110027221A1
公开(公告)日：2011-02-03
申请号：US12529981
申请日：2008-09-24
CPC classification number: A61K8/64 , A61K8/99 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K36/064 , A61K38/1808 , A61K38/1816 , A61K38/1858 , A61K38/193 , A61K38/20 , A61K38/217 , A61K38/30 , A61K38/38 , A61Q5/12 , A61Q11/00 , A61Q19/00 , A61Q19/02 , A61Q19/08 , C07K14/475 , C07K2319/00 , A61K2300/00
Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
Abstract translation: 本发明提供了一种重组融合蛋白，其能刺激皮肤和表皮细胞的复原和再激活，以改善皮肤外观，使皱纹和雀斑平滑，以及美白皮肤。 特别地，本发明提供各种类型的用于改善皮肤的产品，其含有人血清白蛋白（HSA）与细胞因子肽（EGF，FGF，KGF，HGH，HGF，PDGF，GCSF，干扰素，IL-11或 IGF）通过基因工程技术。 融合蛋白可以独立使用或与酵母发酵产物组合使用，或与各种乳化剂，增稠剂，保湿剂，防腐剂，酵母和发酵剂组合使用。
-
公开(公告)号：US20090280085A1
公开(公告)日：2009-11-12
申请号：US12475490
申请日：2009-05-30
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
Abstract translation: 为干扰素类似物提供了组合物，试剂盒和方法，以促进一般健康或治疗疾病。 人类干扰素类似物通过干扰素与人血清白蛋白的融合来制备。 生物测定显示具有相同抗细胞病毒侵袭能力的干扰素类似物在体内比干扰素具有3-10倍的作用功能。 这些新型长效干扰素类似物可用于治疗病毒感染患者，如SARS病毒，HIV，HCV，HBV或HAV，以及癌症疾病如白血病和恶性黑色素瘤。 与干扰素相比，它们的保质期还有3-5倍。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.026 seconds)
